Affordable Access

deepdyve-link
Publisher Website

Chlamydia Treatment Practices and Time to Treatment in Massachusetts: Directly Observed Therapy Versus Pharmacy Prescriptions

Authors
  • Platt, Laura1, 2, 3
  • Elder, Heather3
  • Bassett, Ingrid V.1
  • Molotnikov, Lauren3
  • Klevens, Monina3
  • O’Connor, Erin3
  • Leach, Dylan3
  • Roosevelt, Kathleen3
  • Hsu, Katherine3, 4
  • 1 Massachusetts General Hospital, Boston, MA, USA
  • 2 Brigham and Women’s Hospital, Boston, MA, USA
  • 3 Massachusetts Department of Public Health, Boston, MA, USA
  • 4 Boston Medical Center Division of Pediatric Infectious Diseases, Boston, MA, USA
Type
Published Article
Journal
Journal of Primary Care & Community Health
Publisher
SAGE Publications
Publication Date
Sep 29, 2021
Volume
12
Identifiers
DOI: 10.1177/21501327211044060
PMID: 34583572
PMCID: PMC8485271
Source
PubMed Central
Keywords
Disciplines
  • Original Research
License
Unknown

Abstract

Background Directly observed therapy (DOT) is recommended for the treatment of chlamydia, however pharmacy prescriptions are frequently used. Adherence to DOT and the association between treatment method and time to treatment is unknown. Methods We conducted a retrospective review of a randomized 2% of laboratory-confirmed chlamydia infections reported to the Massachusetts Department of Public Health from January 1, 2019 to May 31, 2019. Clinicians and pharmacies were contacted to ascertain treatment methods and timing. We assessed frequency of DOT and pharmacy prescriptions in the treatment of chlamydia infection in Massachusetts. We used log rank test to compare time to treatment initiation for patients receiving DOT versus pharmacy prescriptions. Data were stratified according to whether treatment was empiric or laboratory-driven. Key results We ascertained full outcomes for 199 patients. Eighty patients received DOT and 119 patients received pharmacy prescriptions. DOT was more common among those receiving empiric treatment and pharmacy prescriptions were more common among those receiving laboratory-driven treatment. The median time to treatment was 1.5 days for patients treated with DOT and 3 days for those treated with pharmacy prescriptions. For both groups, the median time to treatment for empiric therapy was 0 days and for laboratory-driven therapy was 4 days. The differences in time to treatment were not statistically significant. Conclusions Pharmacy prescriptions are frequently used for the treatment of chlamydia in Massachusetts. We did not observe a significant difference in the time to treatment between DOT and pharmacy prescriptions.

Report this publication

Statistics

Seen <100 times